The Effect of Local Subcutaneous Delivery of Vascular Endothelial Growth Factor on the Function of a Chronically Implanted Amperometric Glucose Sensor

Diabetes Technology and Therapeutics

Volumn 6, Issue 2, 2004, Pages 137-145

  Ward, W Kenneth ^a   Wood, Michael D ^a   Casey, Heather M ^a   Quinn, Matthew J ^a   Federiuk, Isaac F ^a  

^a LEGACY RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; VASCULOTROPIN;

AMPEROMETRIC BIOSENSOR; ANALYTICAL ERROR; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG INFUSION; ELECTRODE; FOREIGN BODY; GLUCOSE BLOOD LEVEL; GLUCOSE INFUSION; NONHUMAN; OSMOTIC PUMP; PERMEABILITY; PRIORITY JOURNAL; RAT; TELEMETRY; VASCULARIZATION;

ANIMALS; BIOSENSING TECHNIQUES; BLOOD GLUCOSE; GLUCOSE CLAMP TECHNIQUE; INFUSIONS, PARENTERAL; RATS; RATS, SPRAGUE-DAWLEY; SENSITIVITY AND SPECIFICITY; TELEMETRY; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 1842530340     PISSN: 15209156     EISSN: None     Source Type: Journal    
DOI: 10.1089/152091504773731320     Document Type: Article

References (22)

1. Sharkawy AA, Klitzman B, Truskey GA, Reichert WM: Engineering the tissue which encapsulates subcutaneous implants. II. Plasma-tissue exchange properties. J Biomed Mater Res 1998;40:586-597.
2. Sharkawy AA, Klitzman B, Truskey GA, Reichert WM: Engineering the tissue which encapsulates subcutaneous implants. I. Diffusion properties. J Biomed Mater Res 1997;37:401-412.
3. Sharkawy AA, Klitzman B, Truskey GA, Reichert WM: Engineering the tissue which encapsulates subcutaneous implants. III. Effective tissue response times. J Biomed Mater Res 1998;40:598-605.
4. Gilligan BJ, Shults MC, Rhodes RK, Updike SJ: Evaluation of a subcutaneous glucose sensor out to 3 months in a dog model. Diabetes Care 1994;17:882-887.
5. Updike SJ, Shults MC, Gilligan BJ, Rhodes RK: A subcutaneous glucose sensor with improved longevity, dynamic range, and stability of calibration. Diabetes Care 2000;23:208-214.
6. Ferrara N: Role of vascular endothelial growth factor in the regulation of angiogenesis. Kidney Int 1999;56:794-814.
7. Ferrara N: Molecular and biological properties of vascular endothelial growth factor. J Mol Med 1999;77:527-543.
8. Detmar M, Brown LF, Berse B, Jackman RW, Elicker BM, Dvorak HF, Claffey KP: Hypoxia regulates the expression of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) and its receptors in human skin. J Invest Dermatol 1997;108:263-268.
9. Hippenstiel S, Krull M, Ikemann A, Risau W, Clauss M, Suttorp N: VEGF induces hyperpermeability by a direct action on endothelial cells. Am J Physiol 1998;274(5 Pt 1):L678-L684.
10. Connolly DT: Vascular permeability factor: a unique regulator of blood vessel function. J Cell Biochem 1991;47:219-223.
11. Ward WK, Quinn MJ, Wood MD, Tiekotter KL, Pidikiti S, Gallagher JA: Vascularizing the tissue surrounding a model biosensor: how localized is the effect of a subcutaneous infusion of vascular endothelial growth factor (VEGF)? Biosens Bioelectron 2003;19:155-163.
12. Ward WK, Troupe JE: Assessment of a chronically-implanted subcutaneous glucose sensor in the dog. ASAIO J 1999;45:555-561.
13. Ward WK, Beard JC, Porte D: Islet B-cell function in human subjects. In: Larner J, Clarke WL, Pohl S, eds. Methods of Diabetes Research, Vol. II. New York: John Wiley and Sons, 1986:3-14.
14. Clarke WL, Becker DJ, Cox D, Santiago JV, White NH, Betschart J, Eckenrode K, Levandoski LA, Prusinski EA, Simineiro LM, et al.: Evaluation of a new system for self blood glucose monitoring. Diabetes Res Clin Pract 1988;4:209-213.
15. Weidner N, Folkman J: Tumoral vascularity as a prognostic factor in cancer. In: deVita VT, Hellman S, Rosenberg SA, eds. Important Advances in Oncology. Philadelphia: Lippincott-Raven, 1996:167-190.
16. Weingartner K, Ben-Sasson SA, Stewart R, Richie JP, Riedmiller H, Folkman J: Endothelial cell proliferation activity in benign prostatic hyperplasia and prostate cancer: an in vitro model for assessment. J Urol 1998;159:465-470.
17. Duh E, Aiello LP: Vascular endothelial growth factor and diabetes: the agonist versus antagonist paradox. Diabetes 1999;48:1899-1906.
18. Chawla PS, Keelan MH, Kipshidze N: Angiogenesis for the treatment of vascular diseases [editorial]. Int Angiol 1999;18:185-192.
19. Hopkins SP, Bulgrin JP, Sims RL, Bowman B, Donovan DL, Schmidt SP: Controlled delivery of vascular endothelial growth factor promotes neovascularization and maintains limb function in a rabbit model of ischemia. J Vasc Surg 1998;27:886-894; discussion 895.
20. Lopez JJ, Laham RJ, Stamler A, Pearlman JD, Bunting S, Kaplan A, Carrozza JP, Sellke FW, Simons M: VEGF administration in chronic myocardial ischemia in pigs. Cardiovasc Res 1998;40:272-281.
21. Wieman TJ, Smiell JM, Su Y: Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. A phase III randomized placebo-controlled double-blind study. Diabetes Care 1998;21:822-827.
22. Walder CE, Errett CJ, Bunting S, Lindquist P, Ogez JR, Heinsohn HG, Ferrara N, Thomas GR: Vascular endothelial growth factor augments muscle blood flow and function in a rabbit model of chronic hindlimb ischemia. J Cardiovasc Pharmacol 1996;27:91-98.